Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Diseases × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Neoplasms 5 Lung Neoplasms 4 Neoplasm Metastasis 3 Hematologic Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Solid Tumors 1 Sexual Dysfunction, Physiological 1 Sarcoma 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoproliferative Disorders 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Diseases 1 Glioblastoma 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Carboplatin 14 Pemetrexed 7 Paclitaxel 5 Cisplatin 5 pembrolizumab 4 Nivolumab 4 osimertinib 3 zipalertinib 2 selpercatinib 2 pralsetinib 2 entinostat 2 durvalumab 2 atezolizumab 2 apatinib 2 One-Lung Ventilation 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Bronchoscopy 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 zimberelimab 1 toripalimab 1 taletrectinib 1 spartalizumab 1 sintilimab 1 sacituzumab govitecan 1 repotrectinib 1 patritumab 1 lorlatinib 1 ficlatuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06765109 2026-02-17

ALKAZAR

Nuvalent Inc.

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡